European Companies Search Engine
UK funding (£133,242): Role of the endogenous signalling regulator Similar Expression to FGF (Sef) in growth factor signalling in prostate cancer Ukri12 Apr 2011 UK Research and Innovation, United Kingdom
Overview
Text
Role of the endogenous signalling regulator Similar Expression to FGF (Sef) in growth factor signalling in prostate cancer
| Abstract | Targeting growth factors in prostate cancer Prostate cancer is the commonest male malignancy in the UK (35000 new cases/year). Despite treatment including surgery, many patients will develop a lethal form of disease known as castration resistant prostate cancer. This process is driven in part by molecules called growth factors. We are investigating a gene called Sef which functions as a strong natural inhibitor of growth factors. Our aim is to test if increasing Sef in prostate tumours can enhance treatment designed to block growth factors. If successful, this will offer a new way to treat men with otherwise fatal prostate cancer. |
| Category | Fellowship |
| Reference | G1001961/1 |
| Status | Closed |
| Funded period start | 12/04/2011 |
| Funded period end | 11/04/2013 |
| Funded value | £133,242.00 |
| Source | https://gtr.ukri.org/projects?ref=G1001961%2F1 |
Participating Organisations
| University of Cambridge |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: University of Cambridge, Cambridge.
The visualizations for "University of Cambridge - UK funding (£133,242): Role of the endogenous signalling regulator Similar Expression to FGF (Sef) in growth factor signalling in prostate cancer"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
